INFLARX
InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. In April 2018, InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.
INFLARX
Social Links:
Industry:
Health Care Medical Pharmaceutical Therapeutics
Founded:
2007-12-01
Address:
Jena, Thuringen, Germany
Country:
Germany
Website Url:
http://www.inflarx.de
Total Employee:
11+
Status:
Active
Contact:
+49 (0)3641 508 180
Email Addresses:
[email protected]
Total Funding:
214.83 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Apache Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Altamira Therapeutics
Altamira Therapeutics develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Founder
Stock Details
Investors List
Federal Ministry of Health
Federal Ministry of Health investment in Grant - InflaRx
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - InflaRx
Cormorant Asset Management
Cormorant Asset Management investment in Series D - InflaRx
RA Capital Management
RA Capital Management investment in Series D - InflaRx
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - InflaRx
Staidson Hongkong Investment
Staidson Hongkong Investment investment in Series C - InflaRx
bm-t beteiligungsmanagement thuringen
bm-t beteiligungsmanagement thuringen investment in Series B - InflaRx
Affentranger Associates
Affentranger Associates investment in Series A - InflaRx
bm-t beteiligungsmanagement thuringen
bm-t beteiligungsmanagement thuringen investment in Seed Round - InflaRx
Affentranger Associates
Affentranger Associates investment in Seed Round - InflaRx
Official Site Inspections
http://www.inflarx.de Semrush global rank: 4.18 M Semrush visits lastest month: 2.84 K
- Host name: h2635367.stratoserver.net
- IP address: 85.214.47.114
- Location: Berlin Germany
- Latitude: 52.5174
- Longitude: 13.3985
- Timezone: Europe/Berlin
- Postal: 12529
More informations about "InflaRx"
InflaRx - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +49 (0)3641 508 180 InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of …See details»
CORPORATE PRESENTATION JANUARY 2024 - inflarx.de
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, “InflaRx”). InflaRx (Nasdaq: IFRX) is a biotechnology company …See details»
Pipeline - inflarx.de
InflaRx Pharmaceuticals Inc. 600 S. Wagner Rd. Ann Arbor, MI 48103 . [email protected]. © Copyright 2017 All Rights Reserved. Developed by EmentalsSee details»
InflaRx GmbH - Life-Sciences-Europe.com
Jan 1, 2007 InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit …See details»
InflaRx - The Org
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific …See details»
InflaRx N.V., Munich - life-sciences-europe.com
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. …See details»
InflaRx Company Profile - Office Locations, Competitors ... - Craft
Sep 20, 2024 InflaRx is a biopharmaceutical company developing new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized …See details»
InflaRx Announces Leadership Team Additions with New CFO and …
Sep 17, 2020 For further information please visit www.inflarx.com.Contacts:InflaRx N.V. Jordan Zwick – Chief Strategy Officer Email: jordan.zwick[at]inflarx.de Tel: +1 917-338-6523MC …See details»
About Inflarx
InflaRx Pharmaceuticals Inc. 600 S. Wagner Rd. Ann Arbor, MI 48103 . [email protected]. © Copyright 2017 All Rights Reserved. Developed by EmentalsSee details»
InflaRx: Diesen deutschen Biotech-Senkrechtstarter ... - DER …
Apr 27, 2019 Können die Studiendaten im laufenden Quartal überzeugen, hat InflaRx das Potenzial, zu einem ganz Großen der deutschen Biotech-Szene zu werden. Risikobereite …See details»
InflaRx: Small German Company Targeting A Rare Indication
Sep 6, 2023 InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum …See details»
Forget Humira, InflaRx Has a New Inflammation Treatment on the …
Apr 11, 2018 Indeed, according to Riedemann, InflaRx is the only company with a drug in clinical development that specifically targets C5a. To prove its technology works, InflaRx has been …See details»
InflaRx N.V. (IFRX) Stock Price, News, Quote & History - Yahoo …
The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. www.inflarx.deSee details»
InflaRX - Bain Capital Life Sciences
InflaRx (Nasdaq: IFRX) is a biotechnology company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and …See details»
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA …
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the …See details»
Financial-Information - inflarx.de
Jun 28, 2024 Date: Filing Type: Filing Description: Download / View: 2024-11-15: 6-K: Report of foreign issuer [Rules 13a-16 and 15d-16] 2024-11-08: 6-K: Report of foreign issuer [Rules 13a …See details»
InflaRx N.V. (IFRX) Stock Price, Quote & News - Stock Analysis
3 days ago Website https://www.inflarx.de. Full Company Profile. Financial Performance. Financial numbers in EUR Financial Statements. Analyst Forecast. According to one analyst, …See details»
Investors - inflarx.de
InflaRx Pharmaceuticals Inc. 600 S. Wagner Rd. Ann Arbor, MI 48103 . [email protected]. © Copyright 2017 All Rights Reserved. Developed by EmentalsSee details»
InflaRx Reports Full Year 2021 Financial and Operating Results
Mar 24, 2022 InflaRx’s research and development expenses increased by €10.0 million in the year ended December 31, 2021 compared to the year ended December 31, 2020. This …See details»